Replies to post #141501 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Following gives a heads up on why the company is looking at ulcerative proctitis.

http://cellceutix.com/best-yet-to-come/#sthash.vGj4KtWU.dpbs

GI Diseases

Ulcerative Proctitis

A Phase 2 proof of concept trial for ulcerative proctitis is planned in Q1 2016. We are excited to be pushing forward with this trial earlier than expected. We are constantly exploring diverse indications for which we believe our defensin-mimetic franchise can improve clinical outcomes due to the anti-infective, anti-inflammatory and tissue healing properties of these compounds. A prime target is ulcerative proctitis, a mucosal inflammatory disease of unknown cause involving only the rectum or the distal colon and rectum (proctosigmoiditis). The course of the disease is variable and ranges from complete resolution to easily maintained remission to frequent relapses or refractory disease. Oral or rectal 5-aminosalicyclic acid or corticosteroids are the initial treatments of choice, but long-term use of rectal corticosteroids should be avoided, as they have been known to produce predictable and potentially serious side effects. Brilacidin offers a potential non-corticosteroid treatment that may provide anti-inflammatory effects and be of benefit to patients with these conditions. A successful trial opens up a pathway for multiple GI diseases, which may be a far larger market for Cellceutix then even the anti-infective market for Brilacidin.